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OBJECTIVES This study was designed to document the inflammatory response up to one year after acute
presentation with unstable angina (UA) and non–Q wave infarction (NQMI) as reflected by
the expression of soluble cell adhesion molecules (CAMs).
BACKGROUND Coronary plaque inflammation is a key component in the pathogenesis of acute coronary
syndromes. Cell adhesion molecules are critical mediators of the inflammatory process.
Soluble forms of these molecules are detectable in serum and are elevated acutely in patients
with UA and NQMI.
METHODS Patients presenting with UA and NQMI had serum samples taken at presentation and then
after three, six and 12 months. A control group of similar age and gender distribution was
used for comparison. Levels of soluble inter-cellular adhesion molecule-1, vascular cell
adhesion molecule-1, endothelial-selectin and platelet-selectin were measured using an
ELISA technique.
RESULTS We studied 91 patients (M/F 5 73/18, mean age 62 6 11 years, 56 UA and 35 NQMI) and
24 controls (M/F 5 18/6, mean age 56 6 12 years). Levels of all four soluble CAMs were
significantly elevated in both UA and NQMI patients at presentation, three and six months
in comparison with controls. Levels in UA and NQMI groups fell between six and 12 months
after initial presentation.
CONCLUSIONS The results suggest that the inflammatory stimulus triggering expression of CAMs is
sustained for up to six months after presentation with either UA or NQMI and then returns
toward control values over the following six months. (J Am Coll Cardiol 2000;36:1210–6)
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The pathophysiological mechanisms responsible for unsta-
ble angina (UA) and non–Q wave myocardial infarction
(NQMI) are believed to involve an acute inflammatory
stimulus that contributes to coronary plaque disruption and
subsequent platelet aggregation and vessel thrombosis (1–
7). The hypothesis of an acute inflammatory reaction
playing a role in destabilizing the fibrous tissue cap of the
atherosclerotic plaque is supported by the finding that
inflammatory cells, predominantly macrophages, are present
at the site of plaque erosion or rupture (8). Further evidence
in support of the inflammatory hypothesis comes from the
finding of activated leukocytes in the coronary and systemic
circulation (9), the release of thromboxanes and leukotrienes
related to the occurrence of ischemic chest pain (10) and
elevated levels of the acute phase reactants C-reactive
protein (CRP) and serum amyloid A protein (SSA) in
patients with acute coronary syndromes (11,12). The rise in
CRP in patients with UA occurs independently of myocar-
dial cell injury or death (13,14).
The inflammatory response is associated with the gener-
ation of cytokines and other inflammatory mediators that
induce increased expression of cellular adhesion molecules
(CAMs) (15,16). These CAMs play a critical role in the
adhesion and transendothelial migration of luekocytes from
the blood to the arterial intima (17). Intercellular adhesion
molecule-1 (ICAM-1) is expressed on both resting and
activated endothelial cells and promotes adhesion of neu-
trophils, monocytes and lymphocytes (18). Vascular cell
adhesion molecule-1 (VCAM-1) binds monocytes and
T-lymphocytes to activated endothelial cells (16). Endothe-
lial selectin (E-selectin) is expressed by activated endothelial
cells and binds to mucin like cell adhesion molecules on the
neutrophil surface membrane, thus initiating neutrophil
extravasation (19). Platelet selectin (P-selectin) is similarly
expressed by activated endothelial cells and platelets and
mediates leukocyte adhesion to platelets and endothelial
cells during inflammation, thrombosis and atherosclerosis
(16,20).
The extracellular portion of these adhesion proteins can
be cleaved by proteolytic enzymes to form a circulating
molecules that can be detected in serum and are referred to
as the soluble cell adhesion molecules (sCAMs) (21,22).
Alternative splicing of the messenger RNA encoding for
P-selectin can generate a soluble form of the protein that
can be detected in serum (23). Levels of sICAM-1,
sVCAM-1 and sE-selectin are elevated in patients with UA
and NQMI throughout the first 72 h of acute presentation
(24). Soluble P-selectin levels are elevated in patients with
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UA in comparison with patients with stable angina and
controls (25). The pathological significance of these soluble
forms may be underestimated as they can interfere with
leukocyte-endothelial interactions in vivo as has already
been demonstrated in vitro (26). Alteration in concentra-
tions of these soluble adhesion molecules may relate to
activation or damage of various cell types including platelets
and endothelial cells. There is recent evidence that platelet
activation and inflammation continues for many weeks after
the acute ischemic event in patients with acute coronary
syndromes (27,28). Thus, the primary aim of this study was
to characterize the temporal expression of four soluble
CAMs: sICAM-1, sVCAM-1, sE-selectin and sP-selectin
up to 12 months after acute presentation with either UA or
NQMI.
METHODS
Study population. Study approval was granted by the
institutional ethics review committee, and written informed
consent was obtained from all patients. Patients presenting
acutely with either UA or NQMI were recruited into this
study. Unstable angina was defined according to the Braun-
wald classification as angina at rest within the preceding
24 h, with either ST segment depression (.0.1mV) or
T-wave inversion in two or more contiguous leads on the
presenting electrocardiogram and serum creatine kinase
levels within the normal range (29). Patients in the NQMI
group had similar diagnostic criteria along with an elevation
in creatine kinase.
Our group has recently reported that successful throm-
bolysis causes a significant elevation in levels of sCAMs,
and, thus, we decided not to enroll patients who were
treated with thrombolysis but instead concentrate on pa-
tients with UA and NQMI who receive similar treatment
and have comparable clinical outcomes (30). Study patients
had an initial venous sample taken before commencing
antithrombotic therapy with heparin. The study patients
were monitored in the coronary care unit. Decisions regard-
ing the duration of treatment with antithrombotics and the
need for coronary revascularization were made by the
attending cardiologist. Patients with an active acute or
chronic inflammatory illness, those taking immunosuppres-
sive therapy or those who had taken recent antibiotic
therapy, were excluded from the study. Twenty four volun-
teers in the same age distribution and similar male/female
ratio acted as a healthy control population.
Adhesion molecule estimation. Patients and volunteers
had peripheral venous blood samples taken at presentation
and after 3, 6 and 12 months. These samples were centri-
fuged and serum was stored at 270°C. Levels of sICAM-1,
sVCAM-1, sE-selectin and sP-selectin were measured in
stored sera using enzyme linked immunosorbent assay kits
supplied by R&D Systems (Abingdon, United Kingdom).
The assay is standardized against a purified form of recom-
binant ICAM-1, VCAM-1, E-selectin and P-selectin.
Repeat measurement of 33% of the samples was performed
during each assay to determine the variability of the mea-
surement.
Statistical analysis. Soluble adhesion molecule levels were
measured in ng/ml and expressed as mean 6 SEM for the
UA, NQMI and control groups at each sampling time
point. A two-way analysis of variance (ANOVA) for re-
peated measures was performed to analyze differences in
levels of soluble CAMs between the UA, NQMI and
control groups at different time points. Single factor
ANOVA was used to investigate differences in sCAM levels
among the three groups at each measured time point. A 5%
level of significance was used for the two-way ANOVA and
a 1% level of significance for the single factor ANOVA.
Details of the study and control populations are expressed as
mean 6 standard deviation. A multiple regression analysis
model was used to assess the effect of cardiovascular drug
therapy on the levels of soluble CAMs. The levels sICAM,
sVCAM-1, sE-selectin and sP-selectin were designated as
dependent variables and the cardiovascular drugs outlined in
Table 1. were added to the model in a forward stepping
manner. Statistical analysis was performed with an SPSS
software package.
Abbreviations and Acronyms
ANOVA 5 analysis of variance
CAM 5 cellular adhesion molecule
CRP 5 C-reactive protein
sE-selectin 5 soluble endothelial selectin
sICAM-1 5 soluble intercellular adhesion molecule-1
MI 5 myocardial infarction
NQMI 5 non–Q wave myocardial infarction
sP-selectin 5 soluble platelet selectin
SSA 5 serum amyloid A protein
UA 5 unstable angina
sVCAM-1 5 soluble vascular cell adhesion molecule-1
Table 1. Clinical Characteristics
UA
(n 5 56)
NQMI
(n 5 35)
Controls
(n 5 24)
Age (yrs) 60 6 10 64 6 11* 56 6 11
Male gender (%) 43 (77) 30 (81) 18 (75)
Diabetes mellitus (%) 11 (20) 4 (11) 0
Hypercholesterolemia (%)
(total cholesterol .220
mg/dl)
30 (54) 14 (40) 2 (8)
Smokers (%) 28 (50) 14 (40) 3 (12)
Hypertension (%) 23 (41) 11 (31) 1 (4)
Medications (%)
Aspirin 49 (88) 32 (91) 1 (4)
Beta-blocker 33 (59) 21 (60) 0
Ca blocker 31 (55)* 9 (26) 0
Nitrate 27 (48) 15 (43) 0
ACE inhibitor 17 (30) 11 (31) 1 (4)
HMG CoA 27 (48) 14 (40) 3 (12)
*p , 0.05 NQMI vs. UA.
ACE 5 angiotensin-converting enzyme; Ca 5 calcium; NQMI 5 non–Q wave
myocardial infarction; UA 5 unstable angina.
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RESULTS
Ninety-one patients were enrolled into the study (men/
women 5 73/18), 56 with UA and 35 with NQMI. The
mean age of patients with NQMI was older than those with
UA (64 6 11 years vs. 60 6 10 years, p , 0.05). The
cardiovascular risk factor profiles in both UA and NQMI
groups were similar (Table 1). There was a higher percent-
age of patients in the UA group treated with calcium
antagonists (55% vs. 26%, p , 0.01); otherwise, both
ischemic groups received similar medical treatment. The
major adverse cardiovascular event rate for the duration of
the study was 30% in the UA group and 29% in the NQMI
group (Table 2). There were five deaths during the acute
admission, and one patient was lost to follow-up; thus, there
were 85 patients reviewed three months after discharge.
One further patient died between the three and six month
follow-up visits, and, therefore, there were 84 patients
studied at the six- and 12-month reviews.
A total of 37 (66%) patients in the UA group and 22
(63%) of patients in the NQMI group underwent diagnostic
coronary angiography confirming the presence of coronary
artery disease in all cases. The coronary revascularization
rate was 44% in the UA group and 37% in those with
NQMI (Table 2). The control group consisted of 24 healthy
volunteers (male/female 5 18/6, mean age 56 6 11 years)
who were hospital-based employees with no documented
history nor any symptoms of vascular disease. Among the
control group 3 of 24 (12.5%) were smokers, and one had a
history of hypertension.
sICAM-1. There was no significant difference in the levels
of sICAM-1 at the various measured time points between
the UA and NQMI groups; however, the levels were
elevated at all times in comparison with the control group.
This difference in levels of sICAM-1 between the two study
groups and the control group was statistically significant at
presentation, three and six months (Fig. 1). Levels of
sICAM-1 fell significantly in both the UA and the NQMI
groups between 6 and 12 months: 349 6 12 ng/ml versus
300 6 10 ng/ml, p , 0.01 for UA group and 359 6 26
ng/ml versus 296 6 15 ng/ml, p , 0.05 for NQMI group.
sVCAM-1. There was no significant difference in levels of
sVCAM-1 at the various time points between the UA and
NQMI groups. Levels of sVCAM-1 in both UA and
NQMI groups were significantly elevated at all time points
in comparison with the control group (Fig. 2). Levels of
sVCAM-1 in both UA and NQMI patients increased
between presentation and three months: 810 6 44 ng/ml to
1,004 6 56 ng/ml, p , 0.02 for the UA group and 786 6
78 ng/ml to 930 6 82 ng/ml, p , 0.03 in the NQMI group.
Then levels of sVCAM-1 fell significantly between six and
12 months in both UA and NQMI groups: 892 6 48 ng/ml
versus 744 6 34 ng/ml, p , 0.03 for the UA group and
860 6 63 ng/ml versus 725 6 22 ng/ml, p , 0.05 for the
NQMI group.
sE-selectin. The levels of sE-selectin were elevated in both
ischemic groups in comparison with the control group at
presentation, three and six months, respectively (Fig. 3).
Figure 1. Levels of sICAM-1 in ng/ml in UA, NQMI and control groups at four sampling time points. p values refer to differences in levels of soluble
ICAM-1 between the three groups. #p , 0.05 for levels of sICAM-1 at 6 months versus levels at 12 months in UA and NQMI groups. ICAM-1 5
intercellular adhesion molecule-1; NQMI 5 non–Q wave myocardial infarction; UA 5 unstable angina.
Table 2. Major Adverse Cardiovascular Events
and Revascularization
UA
(n 5 56)
NQMI
(n 5 35)
MACE (%) 17 (30) 10 (29)
Recurrent UA 12 (21) 2 (6)
Nonfatal MI 3 (5) 4 (11)
Cardiovascular death 2 (4) 4 (11)
Revascularization (%) 25 (44) 13 (35)
PCI 17 (30) 10 (29)
CABG 8 (14) 3 (8)
CABG 5 coronary artery bypass grafting; MACE 5 major adverse cardiovascular
events; MI 5 myocardial infarction; NQMI 5 non–Q wave myocardial infarction;
PCI 5 percutaneous coronary intervention; UA 5 unstable angina.
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There was no significant difference in levels of sE-selectin
between the UA and NQMI groups throughout the 12
months of observation. There was a fall in levels of sE-
selectin in both study groups between the 6 and 12 month
sampling period: 52 6 3 ng/ml versus 42 6 3 ng/ml, p ,
0.01 for UA and 56 6 4 ng/ml versus 46 6 4 ng/ml, p ,
0.1 for NQMI.
sP-selectin. Soluble P-selectin levels were significantly el-
evated at all measured time points in both UA and NQMI
groups in comparison with controls (Fig. 4). There was a
trend for levels of sP-selectin to be higher in the patients
with NQMI in comparison with those with UA; however,
this difference failed to achieve statistical significance at any
sampling point. Levels of sP-selectin increased between the
time of presentation and three months follow-up in both
UA and NQMI groups: 113 6 12 ng/ml to 144 6 13
ng/ml, p , 0.03 in the UA group and 120 6 13 ng/ml to
174 6 16 ng/ml p , 0.02 in the NQMI group. Similarly to
levels of the other soluble CAMs, sP-selectin levels fell
significantly in both study groups between 6 and 12 months
after initial presentation: 123 6 10 ng/ml versus 96 6 9
ng/ml, p , 0.02 for UA and 147 6 12 ng/ml versus 113 6
11 ng/ml, p , 0.02 for NQMI.
Clinical outcome and levels of CAMs. Levels of
sVCAM-1 at presentation were significantly elevated in
patients who went on to have a major adverse cardiovascular
event (recurrent UA, nonfatal myocardial infarction, death)
in the six months after the index event: 979 6 30 ng/ml
versus 729 6 22 ng/ml, p , 0.001. There was no significant
difference in the levels of sICAM-1, sE-selectin or sP-
Figure 2. Levels of sVCAM-1 in ng/ml in UA, NQMI and control groups at four sampling time points. p values refer to differences in levels of sVCAM-1
between the three groups. *p , 0.05 for levels of sVCAM-1 in both UA and NQMI groups between presentation and three months. #p , 0.05 for levels
of sVCAM-1 at 6 months versus levels at 12 months in UA and NQMI groups. NQMI 5 non–Q wave myocardial infarction; UA 5 unstable angina;
VCAM-1 5 vascular cell adhesion molecule.
Figure 3. Levels of sE-selectin in ng/ml in UA, NQMI and control groups at four sampling time points. p values refer to differences in levels of sE-selectin
between the three groups. #p , 0.05 for levels of sE-selectin at 6 months versus levels at 12 months in UA and NQMI groups. E-selectin 5 endothelial
selectin; NQMI 5 non–Q wave myocardial infarction; UA 5 unstable angina.
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selectin between those who did and those who did not have
major adverse events. There was no significant change in the
levels of sCAMs in patients taking various cardiovascular
medications including angiotensin-converting enzyme in-
hibitors or HMG-CoA reductase inhibitors over the dura-
tion of the study.
DISCUSSION
The principal finding of this study is that the levels of
sICAM-1, sVCAM-1, sE-selectin and sP-selectin were
elevated in patients presenting acutely with UA and NQMI
in comparison with controls, remained raised for six months
after the index ischemic event and then fell over the
following six months. This study included patients with
both UA as well as NQMI, as similar pathogenic triggers
are responsible for both conditions.
Surface ICAM-1 and VCAM-1 are critically involved
with neutrophil, lymphocyte and monocyte binding and
extravasation at a site of vascular injury (16). These
leukocyte-endothelial cell interactions are mediated by
ICAM-1 or VCAM-1 binding integrins receptors (Mac-1
and VLA-1) on the surface of these inflammatory cells (17).
In vitro models have demonstrated that levels of soluble
CAMs directly reflect endothelial cell surface CAM expres-
sion when cultured endothelial cells are stimulated by
inflammatory cytokines (31). Levels of sICAM-1,
sVCAM-1 and sE-selectin are elevated throughout the first
72 h of acute presentation in patients with UA and NQMI
(24). The persistent elevation of levels of sICAM-1 and
sVCAM-1 after presentation with either UA or NQMI in
this study is suggestive that there is a sustained inflamma-
tory response for up to six months in these patients,
reflecting continued accumulation of inflammatory cells at
the site of vascular injury.
Levels of sE-selectin and sP-selectin also remained ele-
vated for up to six months in patients presenting with the
acute coronary syndromes of UA and NQMI. Endothelial-
selectin is only expressed when endothelial cells are activated
or stimulated (15). Platelet-selectin is released from
Wiebel-Palade bodies of activated endothelial cells and
from alpha granules of activated platelets (32). Both E- and
P-selectin are involved in binding of leukocytes to an area of
activated endothelium initiating the localization of inflam-
matory cells at the site of vascular injury (16). Our findings
suggest that there is continued activation of platelets and
endothelial cells, with consequential upregulation in expres-
sion of surface E- and P-selectin and persistently elevated
levels of E- and P-selectin for up to six months after the
initial ischemic event. The fall in levels of soluble CAMs
between 6 and 12 months may reflect waning of the
inflammatory process.
Interestingly, the levels of both sVCAM-1 and sP-
selectin at three months were significantly elevated in
comparison with the levels at the time of presentation.
These findings support the hypothesis of ongoing inflam-
mation after clinical stabilization but also suggest that
components of the inflammatory process are not maximally
expressed at the time of clinical presentation.
Inflammation in acute coronary syndromes. There is
extensive evidence of both local and systemic inflammation
in acute coronary syndromes. Pathological studies have
demonstrated an inflammatory process at the site of plaque
rupture with a dense inflammatory cell infiltrate and in-
creased local expression of surface CAMs (5,33,34). Acti-
vation of circulating leukocytes, release of thromboxanes
and leukotrienes and increased levels of the inflammatory
marker CRP provide evidence for a systemic inflammatory
reaction in acute coronary syndromes (9–12). Acute coro-
nary syndromes are characterized by persistent instability for
weeks to months after the resolution of the clinical symp-
Figure 4. Levels of sP-selectin in ng/ml in UA, NQMI and control groups at four sampling time points. p values refer to differences in levels of sP-selectin
between the three groups. *p , 0.05 for levels of sP-selectin in both UA and NQMI groups between presentation and three months. #p , 0.05 for levels
of sP-selectin at 6 months versus levels at 12 months in UA and NQMI groups. NQMI 5 non–Q wave myocardial infarction; P-selectin 5 platelet selectin;
UA 5 unstable angina.
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toms, which can result in recurrent episodes of UA pro-
gressing to acute myocardial infarction (MI) or death. There
is recent evidence suggesting that the inflammatory process
continues despite the resolution of clinical symptoms. Bia-
succi et al. (28) reported that serum CRP levels remain
elevated at the time of discharge and at three month
follow-up in up to 50% of patients who presented with
Braunwald IIIB UA, and such an elevation of CRP was
associated with frequent hospital readmission for recurrent
instability (28). Thus, there is a potential link between
recurrent ischemic episodes and persistent inflammatory
stimuli. A recent paper by Ault et al. (27) reported that
there is evidence of continued activation of platelets after an
acute ischemic coronary event. Platelet associated P-selectin
is a sensitive measure of platelet activation; this marker
remained elevated for up to one month after clinical
stabilization after UA or acute MI. Persistent platelet
activation may be a consequence of sustained inflammatory
stimuli. The authors also found a weak correlation between
platelet activation parameters and levels of serum CRP. Our
results strongly support the hypothesis of a persistent
inflammatory response after resolution of clinical symptoms
in patients with acute coronary syndromes.
Clinical relevance. Persistent elevation of acute phase
proteins for up to three months after an ischemic cardiac
event is associated with increased incidence of recurrent
instability within one year (28). The findings of this study
suggest that the inflammatory response remains active for
up to six months after acute presentation with either UA or
NQMI. We recently reported that an elevated level of
sVCAM-1 at presentation in patients with acute coronary
syndromes is associated with an increased risk of recurrent
instability, nonfatal MI and cardiovascular death over the six
months after presentation (35). These data indicate that
inflammatory markers can be used to identify patients at
high risk of major adverse cardiac events and are suggestive
that the intensity of the inflammatory process is associated
with clinical outcome in patients with acute coronary
syndromes. This raises the possibility of designing specific
anti-inflammatory therapies (monoclonal antibodies to
CAMs) for patients at high risk of future ischemic events.
Study limitations. We have assumed that levels of soluble
CAMs sampled from a peripheral vein directly reflect levels
within the coronary circulation, at the site of the athero-
sclerotic plaque erosion or rupture. To resolve this issue we
would have to carry out simultaneous sampling from within
the coronary circulation and from a peripheral vein, which
would be an unethical undertaking in a study requiring
recurrent sampling over a period of 12 months. We did not
address the acute effect of: 1) recurrent ischemic events or 2)
coronary revascularization on the levels of sCAMs in this
study but rather documented the natural time course of
expression of the molecules over a 12 month period after
acute presentation. The acute expression of these molecules
during UA, acute MI and coronary revascularization has
been previously reported (24,25,36,37). Finally we did not
use a group of patients with stable angina as a control group.
Our group and others have previously reported that levels of
sCAMs are elevated in patients with UA in comparison
with patients with stable angina, and these findings are
believed to be a consequence of the acute inflammatory
process involved in the pathogenesis of acute coronary
syndromes. Our aim in this study was to document the
duration of this inflammatory response in patients with UA
and NQMI.
Conclusions. The results of this study indicate that in-
flammatory stimuli, causing increased levels of sCAMs,
persist for up to six months after an episode of UA or
NQMI. The persistence of the inflammatory response and
its association with clinical outcome raises the intriguing
possibility of using the vascular inflammation as a novel
therapeutic target in with acute coronary syndromes. Mono-
clonal antibodies to CAMs could represent an ideal way to
block the leukocyte, endothelial cell and platelet interactions
that are critical in the pathogenesis of these syndromes.
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